Osborne, 13,628 patient aspirin prophylaxis PSM study: 59% lower mortality [p<0.0001] https://c19p.org/osborne
copied to clipboard
Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration
et al., PloS ONE, doi:10.1371/journal.pone.0246825
Retrospective PSM analysis of pre-existing aspirin use in the USA, showing lower mortality with treatment.
|
risk of death, 59.4% lower, RR 0.41, p < 0.001, treatment 272 of 6,300 (4.3%), control 661 of 6,300 (10.5%), NNT 16, odds ratio converted to relative risk, 30 days, PSM.
|
|
risk of death, 60.5% lower, RR 0.40, p < 0.001, treatment 170 of 6,814 (2.5%), control 427 of 6,814 (6.3%), NNT 27, odds ratio converted to relative risk, 14 days, PSM.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Osborne et al., 2/11/2021, retrospective, propensity score matching, USA, North America, peer-reviewed, 6 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.